Clinical relevance of cancer stem cell chemotherapeutic assay for recurrent ovarian cancer

Candace M Howard, Nadim Bou Zgheib, Stephen Bush 2nd, Timothy DeEulis, Antonio Cortese, Antonio Mollo, Seth T Lirette, Krista Denning, Jagan Valluri, Pier Paolo Claudio, Candace M Howard, Nadim Bou Zgheib, Stephen Bush 2nd, Timothy DeEulis, Antonio Cortese, Antonio Mollo, Seth T Lirette, Krista Denning, Jagan Valluri, Pier Paolo Claudio

Abstract

Introduction: Disease recurrence and progression of ovarian cancer is common with the development of platinum-resistant or refractory disease. This is due in large part to the presence of chemo-resistant cancer stem cells (CSCs) that contribute to tumor propagation, maintenance, and treatment resistance. We developed a CSCs drug cytotoxicity assay (ChemoID) to identify the most effective chemotherapy treatment from a panel of FDA approved chemotherapies.

Methods: Ascites and pleural fluid samples were collected under physician order from 45 consecutive patients affected by 3rd-5th relapsed ovarian cancer. Test results from the assay were used to treat patients with the highest cell kill drugs, taking into consideration their health status and using dose reductions, as needed. A retrospective chart review of CT and PET scans was used to determine patients' outcomes for tumor response, time to recurrence, progression-free survival (PFS), and overall survival (OS).

Results: We observed that recurrent ovarian cancer patients treated with high-cell kill chemotherapy agents guided by the CSCs drug response assay had an improvement in the median PFS corresponding to 5.4 months (3rd relapse), 3.6 months (4th relapse), and 3.9 months (5th relapse) when compared to historical data. Additionally, we observed that ovarian cancer patients identified as non-responders by the CSC drug response assay had 30 times the hazard of death compared to those women that were identified as responders with respective median survivals of 6 months vs. 13 months. We also found that ChemoID treated patients on average had an incremental cost-effectiveness ratio (ICER) between -$18,421 and $7,241 per life-year saved (LYS).

Conclusions: This study demonstrated improved PFS and OS for recurrent ovarian cancer patients treated with assay-guided chemotherapies while decreasing the cost of treatment.

Keywords: Cancer Stem Cells; ChemoID; Chemotherapeutic Drug Cytotoxicity Assay; Drug Response Assay; Recurrent Ovarian Cancer.

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Published by Elsevier Inc.

Figures

Fig. 1
Fig. 1
Limiting dilution transplantation assay in immunodeficient animals. A-C) Necroscopic examination of intraperitoneal tumor nodules observed following injections of 1 × 102 CD44, CD133, or CD117 positive ovarian CSCs, respectively. Arrows point at tumor nodules D) Necroscopic examination of intraperitoneal tumor nodules observed following injections of 1 × 102 ChemoID enriched ovarian CSCs. Arrows point at the several tumor nodules formed. E) Necroscopic examination of intraperitoneal tumor nodules observed following injections of 1 × 106 bulk of tumor ovarian cancer cells. Only one tumor was observed in the control bulk of tumor injected mice.
Fig. 2
Fig. 2
Quadrant diagram of the relationship between CSC assay results (%-cell kill on the y-axis) and bulk tumor assay results (%-cell kill on the x-axis) characterized by 6-months recurrence outcomes.
Fig. 3
Fig. 3
Kaplan-Meier plots of overall survival across the study period. Overall survival is shown stratified by dichotomized test results for (A) bulk test >55% cell kill - responder or 40% cell kill - responder or

Fig. 4

Kaplan-Meier plots of progression-free survival…

Fig. 4

Kaplan-Meier plots of progression-free survival across the study period. Progression -free survival is…

Fig. 4
Kaplan-Meier plots of progression-free survival across the study period. Progression -free survival is shown stratified by dichotomized test results for (A) bulk test >55% cell kill - responder or 40% cell kill - responder or

Fig. 5

CT Images and comparative analysis…

Fig. 5

CT Images and comparative analysis of ChemoID test results on Bulk of Tumor…

Fig. 5
CT Images and comparative analysis of ChemoID test results on Bulk of Tumor and Cancer StemCells of a patient affected by third recurrence of an ovarian cancer. A) Baseline CT images show presence of large amount of ascites in December of 2016, with B) ovarian mass measuring 9.3 × 5.4 cm, and C) peritoneal carcinomatosis measuring 3.5 × 5.1 cm. D) Comparative ChemoID analysis on Bulk of Tumor and Cancer Stem Cells obtained from fresh ascites aspirate. E) Control CT images in November of 2017 following a Doxorubicin regimen showing regression of ascites, F) smaller ovarian mass measuring 5.8 × 3 cm, and G) smaller peritoneal carcinomatosis measuring 3.4 × 3 cm.
Similar articles
Cited by
References
    1. Colombo N., Parma G., Bocciolone L., Franchi D., Sideri M., Maggioni A. Medical therapy of advanced malignant epithelial tumours of the ovary. Forum (Genova) 2000;10:323–332. - PubMed
    1. Djordjevic B., Stojanovic S., Conic I., Jankovic-Velickovic L., Vukomanovic P., Zivadinovic R., Vukadinovic M. Current approach to epithelial ovarian cancer based on the concept of cancer stem cells. J Buon. 2012;17:627–636. - PubMed
    1. Wang X., Li X., Fu X., Bai M., Li X., Mei Q., Nie J., Wu Z., Han W. Eliminating ovarian cancer stem cells: a potential therapeutic target for ovarian cancer chemoresistance. Curr. Protein Pept. Sci. 2015;16:270–278. - PubMed
    1. Alvero A.B., Chen R., Fu H.H., Montagna M., Schwartz P.E., Rutherford T., Silasi D.A., Steffensen K.D., Waldstrom M., Visintin I., Mor G. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle. 2009;8:158–166. - PMC - PubMed
    1. Liao J., Qian F., Tchabo N., Mhawech-Fauceglia P., Beck A., Qian Z., Wang X., Huss W.J., Lele S.B., Morrison C.D., Odunsi K. Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism. PLoS One. 2014;9 - PMC - PubMed
Show all 51 references
Related information
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM
Fig. 4
Fig. 4
Kaplan-Meier plots of progression-free survival across the study period. Progression -free survival is shown stratified by dichotomized test results for (A) bulk test >55% cell kill - responder or 40% cell kill - responder or

Fig. 5

CT Images and comparative analysis…

Fig. 5

CT Images and comparative analysis of ChemoID test results on Bulk of Tumor…

Fig. 5
CT Images and comparative analysis of ChemoID test results on Bulk of Tumor and Cancer StemCells of a patient affected by third recurrence of an ovarian cancer. A) Baseline CT images show presence of large amount of ascites in December of 2016, with B) ovarian mass measuring 9.3 × 5.4 cm, and C) peritoneal carcinomatosis measuring 3.5 × 5.1 cm. D) Comparative ChemoID analysis on Bulk of Tumor and Cancer Stem Cells obtained from fresh ascites aspirate. E) Control CT images in November of 2017 following a Doxorubicin regimen showing regression of ascites, F) smaller ovarian mass measuring 5.8 × 3 cm, and G) smaller peritoneal carcinomatosis measuring 3.4 × 3 cm.
Fig. 5
Fig. 5
CT Images and comparative analysis of ChemoID test results on Bulk of Tumor and Cancer StemCells of a patient affected by third recurrence of an ovarian cancer. A) Baseline CT images show presence of large amount of ascites in December of 2016, with B) ovarian mass measuring 9.3 × 5.4 cm, and C) peritoneal carcinomatosis measuring 3.5 × 5.1 cm. D) Comparative ChemoID analysis on Bulk of Tumor and Cancer Stem Cells obtained from fresh ascites aspirate. E) Control CT images in November of 2017 following a Doxorubicin regimen showing regression of ascites, F) smaller ovarian mass measuring 5.8 × 3 cm, and G) smaller peritoneal carcinomatosis measuring 3.4 × 3 cm.

References

    1. Colombo N., Parma G., Bocciolone L., Franchi D., Sideri M., Maggioni A. Medical therapy of advanced malignant epithelial tumours of the ovary. Forum (Genova) 2000;10:323–332.
    1. Djordjevic B., Stojanovic S., Conic I., Jankovic-Velickovic L., Vukomanovic P., Zivadinovic R., Vukadinovic M. Current approach to epithelial ovarian cancer based on the concept of cancer stem cells. J Buon. 2012;17:627–636.
    1. Wang X., Li X., Fu X., Bai M., Li X., Mei Q., Nie J., Wu Z., Han W. Eliminating ovarian cancer stem cells: a potential therapeutic target for ovarian cancer chemoresistance. Curr. Protein Pept. Sci. 2015;16:270–278.
    1. Alvero A.B., Chen R., Fu H.H., Montagna M., Schwartz P.E., Rutherford T., Silasi D.A., Steffensen K.D., Waldstrom M., Visintin I., Mor G. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle. 2009;8:158–166.
    1. Liao J., Qian F., Tchabo N., Mhawech-Fauceglia P., Beck A., Qian Z., Wang X., Huss W.J., Lele S.B., Morrison C.D., Odunsi K. Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism. PLoS One. 2014;9
    1. Vathipadiekal V., Saxena D., Mok S.C., Hauschka P.V., Ozbun L., Birrer M.J. Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PLoS One. 2012;7
    1. Yang L., Lai D. Ovarian cancer stem cells enrichment. Methods Mol. Biol. 2013;1049:337–345.
    1. Hanker L.C., Loibl S., Burchardi N., Pfisterer J., Meier W., Pujade-Lauraine E., Ray-Coquard I., Sehouli J., Harter P., du Bois A. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann. Oncol. 2012;23:2605–2612.
    1. du Bois A., Luck H.J., Meier W., Adams H.P., Mobus V., Costa S., Bauknecht T., Richter B., Warm M., Schroder W. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 2003;95:1320–1329.
    1. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., Mannel R.S., DeGeest K., Hartenbach E.M., Baergen R., Gynecologic Oncology G. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 2003;21:3194–3200.
    1. Ledermann J.A. Primary chemotherapy: the future for the management of advanced ovarian cancer? Int. J. Gynecol. Cancer. 2010;20:S17–S19.
    1. Markman M. The genetics, screening, and treatment of epithelial ovarian cancer: an update. Cleve. Clin. J. Med. 2000;67:294–298.
    1. Foley O.W., Rauh-Hain J.A., del Carmen M.G. Recurrent epithelial ovarian cancer: an update on treatment. Oncology (Williston Park) 2013;27 288-294, 298.
    1. Pujade-Lauraine E., Combe P. Recurrent ovarian cancer. Ann. Oncol. 2016;27(Suppl. 1):i63–i65.
    1. Markman M., Bookman M.A. Second-line treatment of ovarian cancer. Oncologist. 2000;5:26–35.
    1. Matsuo K., Eno M.L., Im D.D., Rosenshein N.B. Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas. Arch. Gynecol. Obstet. 2010;281:325–328.
    1. NCCN . 2015. Clinical Practice Guidelines in Oncology: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer Version 2.2015.
    1. Fotopoulou C., Zang R., Gultekin M., Cibula D., Ayhan A., Liu D., Richter R., Braicu I., Mahner S., Harter P. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation. Ann. Surg. Oncol. 2013;20:1348–1354.
    1. Stockler M.R., Hilpert F., Friedlander M., King M.T., Wenzel L., Lee C.K., Joly F., de Gregorio N., Arranz J.A., Mirza M.R. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J. Clin. Oncol. 2014;32:1309–1316.
    1. Pujade-Lauraine E., Hilpert F., Weber B., Reuss A., Poveda A., Kristensen G., Sorio R., Vergote I., Witteveen P., Bamias A. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J. Clin. Oncol. 2014;32:1302–1308.
    1. Aghajanian C., Blank S.V., Goff B.A., Judson P.L., Teneriello M.G., Husain A., Sovak M.A., Yi J., Nycum L.R. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 2012;30:2039–2045.
    1. Aghajanian C., Goff B., Nycum L.R., Wang Y.V., Husain A., Blank S.V. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol. Oncol. 2015;139:10–16.
    1. Coleman R.L., Brady M.F., Herzog T.J., Sabbatini P., Armstrong D.K., Walker J.L., Kim B.G., Fujiwara K., Tewari K.S., O'Malley D.M. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:779–791.
    1. McGee J., Bookman M., Harter P., Marth C., McNeish I., Moore K.N., Poveda A., Hilpert F., Hasegawa K., Bacon M. Fifth ovarian cancer consensus conference: individualized therapy and patient factors. Ann. Oncol. 2017;28:702–710.
    1. Havrilesky L.J., Krivak T.C., Mucenski J.W., Myers E.R. Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer. Am. J. Obstet. Gynecol. 2010;203(160):e161–e167.
    1. Plamadeala V., Kelley J.L., Chan J.K., Krivak T.C., Gabrin M.J., Brower S.L., Powell M.A., Rutherford T.J., Coleman R.L. A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer. Gynecol. Oncol. 2015;136:94–98.
    1. Kelly S.E., Di Benedetto A., Greco A., Howard C.M., Sollars V.E., Primerano D.A., Valluri J.V., Claudio P.P. Rapid selection and proliferation of CD133+ cells from cancer cell lines: chemotherapeutic implications. PLoS One. 2010;5
    1. Mathis S.E., Alberico A., Nande R., Neto W., Lawrence L., McCallister D.R., Denvir J., Kimmey G.A., Mogul M., Oakley G., 3rd Chemo-predictive assay for targeting cancer stem-like cells in patients affected by brain tumors. PLoS One. 2014;9
    1. Cortese A., Pantaleo G., Amato M., Lawrence L., Mayes V., Brown L., Sarno M.R., Valluri J., Claudio P.P. A new complementary procedure for patients affected by head and neck cancer: chemo-predictive assay. Int. J. Surg. Case Rep. 2016;26:42–46.
    1. DeEulis T., Howard C.M., Valluri J., Claudio P.P. Efficacy of ChemoID guided drug selection for palliative chemotherapy in advanced recurrent high-grade ovarian adenocarcinoma: case study. Transl Med Rep. 2017;1:70–75.
    1. Howard CM, Alberico A, Valluri J, Griswold M, Claudio PP: Analysis of chemo-predictive assay for targeting cancer stem cells in 41 glioblastoma patients. In J Clin Oncol, vol. 35. pp. (suppl; abstr e13544); 2017:(suppl; abstr e13544).
    1. Howard C.M., Valluri J., Alberico A., Julien T., Mazagri R., Marsh R., Alastair H., Cortese A., Griswold M., Wang W. Analysis of chemopredictive assay for targeting cancer stem cells in glioblastoma patients. Transl. Oncol. 2017;10:241–254.
    1. Ranjan T., Howard C.M., Yu A., Xu L., Aziz K., Jho D., Leonardo J., Hameed M.A., Karlovits S.M., Wegner R.E. Cancer stem cell chemotherapeutics assay for prospective treatment of recurrent glioblastoma and progressive anaplastic glioma: a single-institution case series. Transl. Oncol. 2020;13:100755.
    1. Cortese A., Amato M., Pantaleo G., Claudio P.P. A patient with a rare single mandibular localization of non-Hodgkin B-cell lymphoma: early differential diagnosis with dental lesions. J. Craniofac. Surg. 2015;26:e365–e366.
    1. CMS Reimbursement Rates, Part B Drugs. Accessed April 3, 2020 [].
    1. CMS Physician Fee Schedule. Accessed April 5, 2020 [].
    1. Havrilesky L.J., Secord A.A., Kulasingam S., Myers E. Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. Gynecol. Oncol. 2007;107:211–218.
    1. Visvader J.E. Cells of origin in cancer. Nature. 2011;469:314–322.
    1. Kreso A., Dick J.E. Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14:275–291.
    1. Tang D.G. Understanding cancer stem cell heterogeneity and plasticity. Cell Res. 2012;22:457–472.
    1. Howard C.M., Valluri J., Claudio P.P. Functional drug response assay for cancer stem cells in the era of precision medicine. Translational Med. Rep. 2017;1
    1. Ahmed N., Abubaker K., Findlay J., Quinn M. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J. Cell. Biochem. 2013;114:21–34.
    1. Ahmed N., Abubaker K., Findlay J.K. Ovarian cancer stem cells: molecular concepts and relevance as therapeutic targets. Mol. Asp. Med. 2014;39:110–125.
    1. Bapat S.A., Mali A.M., Koppikar C.B., Kurrey N.K. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 2005;65:3025–3029.
    1. Burgos-Ojeda D., Rueda B.R., Buckanovich R.J. Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer Lett. 2012;322:1–7.
    1. Schink J.C., Copeland L.J. Point: chemosensitivity assays have a role in the management of recurrent ovarian cancer. J. Natl. Compr. Cancer Netw. 2011;9:115–120.
    1. Herzog T.J., Krivak T.C., Fader A.N., Coleman R.L. Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Am. J. Obstet. Gynecol. 2010;203(68):e61–e66.
    1. Tian C., Sargent D.J., Krivak T.C., Powell M.A., Gabrin M.J., Brower S.L., Coleman R.L. Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study. Br. J. Cancer. 2014;111:843–850.
    1. Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S, Group TCAOCT A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anti-Cancer Drugs. 2007;18:1093–1101.
    1. Grendys E.C., Jr., Fiorica J.V., Orr J.W., Jr., Holloway R., Wang D., Tian C., Chan J.K., Herzog T.J. Overview of a chemoresponse assay in ovarian cancer. Clin. Transl. Oncol. 2014;16:761–769.
    1. Haslem D.S., Chakravarty I., Fulde G., Gilbert H., Tudor B.P., Lin K., Ford J.M., Nadauld L.D. Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs. Oncotarget. 2018;9:12316–12322.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner